Long-Acting Drug Delivery Systems: Pharmaceutical, Clinical, and Regulatory Aspects

Dr Eneko Larrañeta is a Lecturer in Pharmaceutical Sciences at the School of Pharmacy Queen’s University Belfast. He worked in different multidisciplinary first-class laboratories developing drug delivery systems. His research area falls within the interface of pharmaceutics, chemistry, engineering and biomedical sciences. During his independent career, he developed research projects for industrial partners (L’Oreal) and research councils (Wellcome Trust, Royal Society, PATH among others). To date, he has published more than 40 peer-reviewed papers in leading international journals, as well as 4 book chapters, 1 invited presentation and 11 conference abstracts, describing a range of advanced drug delivery systems, including nanoparticles and microneedles. Dr Thakur obtained his PhD in Drug Delivery from School of Pharmacy, Queens University Belfast (2009), M.Sc in Pharmaceutical Sciences from University Science Malaysia (2006) and B.Pharm from Jawaharlal Nehru Technological University, India (2002). His current research involves the fabrication and design of novel long-acting injectable and implantable drug delivery systems for treating back of the eye disorders. Dr Thakur's ocular drug delivery research has led to the formation of Re-Vana?Therapeutics Ltd. He is currently acting as the CSO for Re-Vana. He is Chair for Ocular Delivery (OcD) Focus Group?supported by the mission of Controlled Release Society (CRS). He has authored over 150 scientific publications, including 52 peer-reviewed research papers, 10 book chapters and 4 textbooks. He has been an invited speaker at a number of national/international meetings. He is currently Editorial Board member of the International Journal of Pharmacy & Pharmacology, Chronicles of Pharmacy and SCIENCEDOMAIN?international, and?Scientific advisor for Journal of Pharmaceutical Sciences. Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology. His research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and topical drug delivery, with a strong emphasis on improving therapeutic outcomes for patients. His bioadhesive patch design was used successfully in the clinic and has now been licensed to Swedish Pharma AB, for whom he acts as a Scientific Advisor. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with the world’s leading transdermal patch manufacturer and several major pharma partners. Still at a relatively early stage of his career, he has obtained substantial RCUK, charity and industrial funding and authored over 300 peer-reviewed publications, including 4 patent applications, 4 textbooks, 19 book chapters and approximately 130 full papers. He has been an invited speaker at numerous national and international conferences.

1 Overview of the clinical current needs and potential applications for long-acting and implantable delivery systems 2 Classification, material types, and design approaches of long-acting and implantable drug delivery systems 3 Long-acting drug delivery systems for ocular therapies 4 Applications of long-lasting and implantable drug delivery systems for cardiovascular disease treatment 5 Implantable and long-lasting drug delivery systems for cancer treatment 6 Long-acting drug delivery systems: applications for sexual and reproductive health 7 Long-acting drug delivery systems for schizophrenia treatment 8 Implantable and long-lasting drug delivery systems for infectious, inflammatory, endocrine, and neurodegenerative diseases 9 Long-lasting drug delivery systems based on microneedles 10 Safety, biodegradability, and biocompatibility considerations of long-acting drug delivery systems 11 Characterization methodologies for long-acting and implantable drug delivery systems 12 Challenges for clinical translation of long-acting and implantable drug delivery systems